At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed May 12, 2026 at 08:00 ET
Rhythm Pharmaceuticals presented positive clinical data for setmelanotide at ECE 2026, including significant BMI reductions (16.9% at 12 months) and improvements in cardiometabolic risk indices in acquired hypothalamic obesity. The data are encouraging but represent incremental conference presentations rather than a regulatory or financial catalyst.
- Real-world data showed 16.9% mean BMI reduction at 12 months in acquired HO (n=25, p<0.0001).
- Phase 3 TRANSCEND post hoc analysis: metabolic syndrome z-score improved -0.9 vs -0.2 placebo (p<0.0001).
- No new safety signals; adverse events consistent with prior Phase 3 trials.
- Six posters presented at ECE 2026; none represent regulatory filings or label expansions.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access